CN101234085A - Docetaxel-containing anti-cancer sustained-release injection - Google Patents
Docetaxel-containing anti-cancer sustained-release injection Download PDFInfo
- Publication number
- CN101234085A CN101234085A CNA2008103002342A CN200810300234A CN101234085A CN 101234085 A CN101234085 A CN 101234085A CN A2008103002342 A CNA2008103002342 A CN A2008103002342A CN 200810300234 A CN200810300234 A CN 200810300234A CN 101234085 A CN101234085 A CN 101234085A
- Authority
- CN
- China
- Prior art keywords
- docetaxel
- slow
- combination
- cell toxicity
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to anticancer sustained release injection which comprises sustained release microspheres and menstruum, wherein, the sustained release microspheres comprise anticancer active components and sustained release auxiliary material; the menstruum is special menstruum that contains suspending agent. The anticancer active components are fotemustine, nimustine, carmustine or combination of bendamustine and mitozolomide, docetaxel, etoposide, teniposide, vinblastine, anastrozole, tamoxifen, fluorouracil or mitomycin C; the sustained release auxiliary material is polylactic acid and polylactic acid copolymer, polyethylene glycol and polylactic acid copolymer of polyethylene glycol, terminal carboxyl group polylactic acid copolymer, EVAc, fatty acid and decanedioic acid copolymer, etc.; viscosity of the suspending agent is 100cp-3,000cp (at 25 DEG C-30 DEG C), and the suspending agent is selected from sodium carboxymethylcellulose, etc. The sustained release microspheres can also be made into sustained release implant; the injection or implant is injected or placed in or around tumor so as to reduce general reaction of the drug and selectively improve and keep local concentration for about 30-50 days. The anticancer sustained release injection can be used solely and can also promote anti-tumor effects of non-operative treatments, such as chemotherapy and/or radiotherapy, etc.
Description
(1) technical field
The present invention relates to a kind of anticancer sustained-release agent and preparation method thereof, belong to technical field of pharmaceuticals.Particularly, the invention provides a kind of anticancer medicine slow-release preparation containing that contains fotemustine and cell toxicity medicament, be mainly slow releasing injection and sustained-release implant.
(2) background technology
As one of cancer conventional treatments, chemotherapeutics has been widely used in the treatment of multiple malignant tumor, and action effect is comparatively obvious.Yet its tangible general toxicity has greatly limited the application of this medicine.
Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy, be difficult to tumor by local and form effective drug level, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.Pharmaceutical topical application may solve the problem of drug level to a certain extent, yet operation techniques such as medicine implantation are complicated, traumatic big, the various complication such as, infection hemorrhage, immunity reduction, also can cause or quicken the diffusion and the transfer of tumor except that easily causing.In addition, the preparation of perioperatively itself and expensive expense usually influence its effective enforcement.In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote its infiltrative growth " (referring to beam etc. " increased the Drug tolerance of human lung carcinoma cell and external wetting capacity after the cancer therapy drug pulse screening and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., Int J Cancer.2004; 111 (4): 484-93)).
Moreover, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fibrin and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and the infiltration in the tumor tissues and diffusion (carry and to wait " situation of extracellular matrix to entity tumor in the medicine influence of turning round " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503)).Therefore, be convenient to keep high drug level and increase tumor cell the preparation and the method for the sensitivity of medicine just become an important subject at tumor by local.
(3) summary of the invention
Fotemustine or cell toxicity medicament have been widely used in the multiple entity tumor of treatment both at home and abroad, as the cerebral tumor, cancer of pancreas, breast carcinoma, pulmonary carcinoma, colon cancer etc. as new or commonly used cancer therapy drug.Yet in application process, its tangible general toxicity has greatly limited the application of this medicine.
Be effectively to improve tumor by local drug level, reduce the drug level of medicine in blood circulation, people have studied the slow-released system that contains cancer therapy drug, comprise that sustained-release micro-spheres (capsule) (sees: Chinese patent (patent No. ZL00809160.9; Application number 91109723.6), Ciftci K etc. " with the polylactic acid microsphere treatment entity tumor that contains fluorouracil and the research of drug release " " drug development technology (Pharm Dev Technol.) 2 (2): 151-60,1997), sustained-release implant (sees: China Patent No. ZL96115937.5; ZL97107076.8) etc.Yet, solid sustained-release implant (China Patent No. ZL96115937.5; ZL97107076.8) and existing as be used for the treatment of the cerebral tumor (ZL00809160.9) sustained-release micro-spheres or United States Patent (USP) (US5,651,986) and all have problem such as be not easy more than operation, weak curative effect, the complication.In addition, the sensitivity that many entity tumors are drawn together fotemustine to anticancer medicated bag is relatively poor, and is easy to generate drug resistance in therapeutic process.The present invention finds that cell toxicity medicament of mentioning among the present invention and fotemustine share and can make its antitumaous effect strengthen (the following cell toxicity medicament that the fotemustine antitumaous effect will be increased mutually is referred to as the fotemustine synergist) mutually.In addition, with the assembly packaging of fotemustine and its synergist in specific slow-release auxiliary material and be equipped with special solvent and make drug level that anti-cancer medicine sustained-release injection not only can greatly improve tumor by local, reduce the drug level of medicine in blood circulation, reduce the toxicity of medicine to normal structure, can also greatly make things convenient for the medicine injection, reduce operation technique complication, reduce patient's expense.The cell toxicity medicament decapacitation suppresses can also increase the sensitivity of tumor cell to fotemustine outside the tumor growth.The above unexpected main contents of the present invention of finding to constitute.
The present invention is directed to the deficiencies in the prior art, a kind of new slow releasing agent that contains fotemustine and/or cell toxicity medicament is provided, comprise slow releasing injection and sustained-release implant.
Fotemustine slow releasing injection of the present invention is made up of sustained-release micro-spheres and solvent.Particularly, this slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent.
Wherein,
Anticancer effective component is fotemustine and cell toxicity medicament;
Slow-release auxiliary material range of viscosities IV (dl/g) is 0.1～0.8, be selected from poly-dl-lactide (D, L-PLA), poly-dl-lactide/ethanol copolymer (D, L-PLGA), monomethyl polyethylene glycol (MPEG-PLA), monomethyl polyethylene glycol copolymer (MPEG-PLGA), polyethylene glycol (PLA-PEG-PLA), polyethylene glycol copolymer (PLGA-PEG-PLGA), end carboxyl polylactic acid (PLA-COOH), end carboxyl polylactic acid/ethanol copolymer (PLGA-COOH), polifeprosan, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)], ethylene vinyl acetate copolymer (EVAc), polylactic acid (PLA), the copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), PPDO (PDO), PTMC (PTMC), xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, one of albumin glue or its combination; Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
Conventional route administrations such as main oral administration of cancer therapy drug or intravenous injection, administering mode of the present invention is the local sustained release administration, obviously reduces the toxic action of its whole body in the therapeutic effect that significantly strengthens medicine.The anticancer active constituent of having reported of using through the slow release approach is a lot, is not all slow release effects that all can reach effective release in slow-release auxiliary material.Pharmaceutic adjuvant have hundreds of more than, pharmaceutic adjuvant with slow releasing function, it is not apparent particularly selected fotemustine among the present invention slowly being discharged in the regular hour in human body or animal body, but specific slow-release auxiliary material need could be determined through a large amount of creative works with the selection of slow releasing pharmaceutical combination.The data of release characteristics need could obtain through a large amount of creationary experiments in inside and outside in the related data, particularly animal body, are not just can determine to have unobviousness through limited experiment.
Fotemustine among the present invention also can be replaced by bendamustine, carmustine, nimustine, lomustine, estramustine, Sarmustine SarCNU, and is similar to fotemustine because the present invention finds its mechanism of action.Shared ratio in compositions such as fotemustine is decided because of concrete condition, can be 0.1%-50%, is good with 1%-40%, and 5%-30% is best.
Cell toxicity medicament comprises and is selected from one of hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) and ametycin or its combination.
The percentage by weight of above-mentioned cell toxicity medicament in slow releasing agent is good from 0.01%-99.99% with 1%-50%, is best with 5%-30%.
When the anticancer effective component in the medicament slow-release microsphere only was fotemustine or cell toxicity medicament, slow-releasing anticarcinogen injection was mainly used in the fotemustine of other approach application of increase or the action effect of cell toxicity medicament, or was used for the potentiation to radiotherapy or other therapies.When the anticancer effective component in the medicament slow-release microsphere only was fotemustine or its synergist (cell toxicity medicament), the application of slow-releasing anticarcinogen injection and potentiation mode were:
(1) contain the slow releasing injection local injection of fotemustine, and cell toxicity medicament is used through other approach;
(2) local injection contains the slow releasing injection of cell toxicity medicament, and other approach are used fotemustine;
(3) local injection contains the slow releasing injection and the slow releasing injection that contains cell toxicity medicament of fotemustine; Or
(4) local injection contains the slow releasing injection of fotemustine and cell toxicity medicament.
The slow-releasing anticarcinogen injection of topical application also is used for the potentiation to radiotherapy or other therapies.Other approach refer to, but are not limited to tremulous pulse, vein, abdominal cavity, subcutaneous, intracavitary administration.
Anticancer effective component fotemustine and/or the cell toxicity medicament percentage by weight in medicament slow-release microsphere is 0.5%-60%, is good with 2%-40%, is best with 5%-30%.The weight ratio of fotemustine and cell toxicity medicament is 1-9: 1 to 1: 1-9, with 1-2: 1 serves as preferred.
Anticancer effective component in the slow-releasing anticarcinogen injection microsphere of the present invention is preferably as follows, and all is weight percentage:
(1) cell toxicity medicament of the fotemustine of 2-40%, carmustine or nimustine and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(2) cell toxicity medicament of the bendamustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(3) cell toxicity medicament of the lomustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(4) cell toxicity medicament of the estramustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin; Or
(5) cell toxicity medicament of the Sarmustine SarCNU of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin.
Slow-release auxiliary material can be various water solublity or water-insoluble macromolecule polymer, preferred poly-dl-lactide in multiple slow-release auxiliary material, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, one of gelatin and albumin glue or its combination.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release micro-spheres of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) EVAc of 55-90%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or white tempera; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
In various high molecular polymers, with polylactic acid, decanedioic acid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, glycolic and hydroxy carboxylic acid, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.The blend ratio of glycolic and hydroxy carboxylic acid is 10/90-90/10 (weight), preferably 25/75-75/25 (weight).The method of blend is arbitrarily.Content when glycolic and hydroxy carboxylic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is polifeprosan [poly-(1,3-two (to the carboxyl phenoxy group) propane-decanedioic acid) (p (CPP-SA)), bis-fatty acid-decanedioic acid copolymer (PFAD-SA)], poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)] and poly-(fumaric acid-decanedioic acid) [P (FA-SA)] etc.Content during to carboxylic phenoxypropane (p-CPP) and decanedioic acid copolymerization is respectively percentage by weight 10-60% and 20-90%, and the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
The molecular weight peak value of polylactic acid can be, but is not limited to, 5000-100, and 000, but with 20,000-60,000 is preferred, with 5,000-30,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, 5000-100, and 000, but with 5,000-50,000 is preferred, with 10,000-30,000 for most preferably; Above polyhydroxy acid can singly select or multiselect.When singly selecting, serve as preferred with the copolymer (PLGA) of polylactic acid (PLA) or hydroxy carboxylic acid and glycolic, the molecular weight of copolymer can be, but is not limited to, 5000-100,000, but with 20,000-60,000 be preferably, with 30,000-50,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or decanedioic acid or copolymer for most preferably, as, but be not limited to, molecular weight is 1000 to 30000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 30000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 20000 to 30000 polylactic acid mixes with decanedioic acid, molecular weight is that 30000 to 80000 PLGA mixes with decanedioic acid.Used polylactic acid serves as preferred with Poly-L-lactic acid (L-PLA).Poly-L-lactic acid (L-PLA) range of viscosities IV (dl/g) is 0.2～0.8, and glass transition temperature range is 55～65 ℃, 175～185 ℃ of fusing points.
Except that above-mentioned slow-release auxiliary material, also can select for use other materials to see the United States Patent (USP) (patent No. 4757128; 4857311; 4888176; 4789724) and in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor) have a detailed description.In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvant, comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
For regulating drug releasing rate or changing other characteristic of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide, (sulphuric acid) chrondroitin and chitin etc., and wherein salt can be, but is not limited to, potassium salt and sodium salt etc.; Also can add other pharmaceutic adjuvant, as, but be not limited to filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or blocker etc.
In the slow releasing injection, drug sustained release system can be made into microsphere, sub-micro ball, microemulsion, nanosphere, granule or spherical piller, makes the injection use then with after the injection solvent mixes.In various slow releasing injection, serve as preferred with the suspension type slow releasing injection, the suspension type slow releasing injection is the preparation that the drug sustained release system that will contain anticancer component is suspended in gained in the injection, used slow-release auxiliary material is a kind of or its combination in the above-mentioned slow-release auxiliary material, and used solvent is common solvent or the special solvent that contains suspending agent.Common solvent is, but is not limited to the buffer that distilled water, water for injection, physiology are prepared towards liquid, dehydrated alcohol or various salt.The purpose of suspending agent is the pastille microsphere that effectively suspends, thereby is beneficial to the usefulness of injection.Be convenient injection, the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).Suspending agent is selected from one of sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40 and soil temperature 80 or its combination.
The content of suspending agent in common solvent is decided because of its characteristic, can be 0.1-30% and decides because of concrete condition.Consisting of of preferred suspending agent:
A) 0.5-5% sodium carboxymethyl cellulose+0.1-0.5% soil temperature 80; Or
B) 5-20% mannitol+0.1-0.5% soil temperature 80; Or
C) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% soil temperature 80.
The kind of solvent is then depended in the preparation of solvent, and common solvent has commercially available, also can make by oneself, and as distilled water, water for injection, physiology buffer towards liquid, dehydrated alcohol or the preparation of various salt, but must be in strict accordance with related standards.Special solvent need be considered the kind of suspending agent and the medicine that composition, solvent suspended, composition, character and the requirement thereof of sustained-release micro-spheres (or microcapsule) and the preparation method of injection, as sodium carboxymethyl cellulose (1.5%)+mannitol and/or sorbitol (15%) and/or Tween 80 (0.1%) are dissolved in the normal saline mutually deserved solvent, viscosity is at 10cp-650cp (20 ℃-30 ℃ time).
The present invention finds to influence medicine and/or sustained-release micro-spheres suspends and/or the key factor of injection is the viscosity of solvent, and viscosity is big more, and suspension effect is good more, and syringeability is strong more.This unexpected one of main index characteristic of the present invention of finding to have constituted.The viscosity of solvent depends on the viscosity of suspending agent, and the viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), preferred 1000cp-3000cp (20 ℃-30 ℃ time), most preferably 1500cp-3000cp (20 ℃-30 ℃ time).According to the viscosity of the prepared solvent of this condition is 10cp-650cp (20 ℃-30 ℃ time), preferred 20cp-650cp (20 ℃-30 ℃ time), most preferably 60cp-650cp (20 ℃-30 ℃ time).
The preparation of injection has several different methods, and a kind of is that the sustained-release microparticle (A) of suspending agent for " 0 " directly mixed in special solvent, obtains corresponding sustained-release microparticle injection; Another kind is that suspending agent is not mixed in special solvent or common solvent for the sustained-release microparticle (A) of " 0 ", obtains corresponding sustained-release microparticle injection; Another is that sustained-release microparticle (A) is mixed in common solvent, adds the suspending agent mixing then, obtains corresponding sustained-release microparticle injection.Except, also can earlier sustained-release microparticle (A) be mixed and in special solvent, make corresponding suspension, with the moisture in ways such as the vacuum drying removal suspension, special solvent of reuse or common solvent suspendible obtain corresponding sustained-release microparticle injection afterwards then.Above method just is illustrative rather than definitive thereof the present invention.It should be noted that suspended drug or sustained-release micro-spheres (or microcapsule) concentration in injection decide because of specifically needing, can be, but be not limited to, 10-400mg/ml, but be preferably with 30-300mg/ml, with 50-200mg/ml most preferably.The viscosity of injection is 50cp-1000cp (20 ℃-30 ℃ time), preferred 100cp-1000cp (20 ℃-30 ℃ time), most preferably 200cp-650cp (20 ℃-30 ℃ time).This viscosity is applicable to 18-22 injection needle and special bigger (to 3 millimeters) injection needle of internal diameter.
The preparation method of slow releasing injection is arbitrarily, available some kinds of methods preparation: as, but be not limited to, mixing method, fusion method, dissolution method, spray drying method for preparation microsphere, dissolution method are made micropowder, liposome bag medicine method and emulsion process etc. in conjunction with freezing (drying) comminuting method.Serve as preferred wherein with dissolution method (being the solvent volatility process), seasoning, spray drying method and emulsion process.Microsphere then can be used for preparing above-mentioned various slow releasing injection, and its method is arbitrarily.The particle size range of used microsphere can be between 5-400um, serving as preferred between the 10-300um, with between the 20-200um for most preferably.
Microsphere also can be used for preparing other slow releasing injection, as gel injection, block copolymer micelle injection.Wherein, block copolymer micelle is formed in aqueous solution by hydrophobic-hydrophilic block copolymers, has spherical inner core-shell mechanism, and hydrophobic block forms kernel, and hydrophilic block forms shell.The carrier micelle injection enters the purpose that reaches control drug release or targeted therapy in the body.Used pharmaceutical carrier is above-mentioned any one or its combination.Wherein preferred molecular weight is the hydrophilic block of the Polyethylene Glycol (PEG) of 1000-15000 as the micelle copolymer, and preferred biological degradation polyalcohol (as PLA, polylactide, polycaprolactone and copolymer thereof (molecular weight 1500-25000)) is as the hydrophobic block of micelle copolymer.The particle size range of block copolymer micelle can be between 10-300um, between the 20-200um serving as preferred.Gel injection system is dissolved in some amphipathic solvent with biological degradation polyalcohol (as PLA, PLGA or DL-LA and epsilon-caprolactone copolymer), adds medicine miscible with it (or suspendible) back again and forms flowability gel preferably, can be through tumor week or intratumor injection.In case inject, amphipathic solvent diffuses to body fluid very soon, the moisture in the body fluid then infiltrates gel, makes polymer cure, slowly discharges medicine.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, used pharmaceutic adjuvant can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, the certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid are first-selection, mixture and copolymer can be selected from, but be not limited to PLA, PLGA, the mixture of PLA and PLGA, the mixture or the copolymer of certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride, bis-fatty acid and decanedioic acid copolymer (PFAD-SA), poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)], poly-(fumaric acid-decanedioic acid) [P (FA-SA)].Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40: 50-90, preferably weight ratio 15-30: 65-85.
Another form of anticancer medicine slow-release preparation containing of the present invention is that anticancer medicine slow-release preparation containing is a sustained-release implant.The effective ingredient of anticancer implant can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion and/or the mode of degrading through polymer.
The characteristics of sustained-release implant are that used slow-release auxiliary material removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, blocker, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
The Main Ingredients and Appearance of sustained-release implant can be made into multiple dosage form.As, but be not limited to capsule, slow releasing agent, implant, slow releasing agent implant etc.; Be multiple shape, as, but be not limited to granule, pill, tablet, powder, sphere, bulk, needle-like, bar-shaped, column and membranaceous.In various dosage forms, serve as preferred slowly to discharge implant in the body.Can be the bar-shaped of 0.1-5mm (slightly) * 1-10mm (length), also can be other shapes such as lamellar.
The most preferred dosage form of sustained-release implant is that the slow releasing agent that biocompatibility, degradable absorb is implanted, and can make different shape and various dosage form because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, drying, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.
Slow-release auxiliary material can be various water solublity or water-insoluble macromolecule polymer, and the anticancer effective component and the percentage by weight of anti-cancer sustained-released implantation agent of the present invention are preferably as follows:
(1) cell toxicity medicament of the fotemustine of 2-40%, carmustine or nimustine and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(2) cell toxicity medicament of the bendamustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(3) cell toxicity medicament of the lomustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(4) cell toxicity medicament of the estramustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin; Or
(5) cell toxicity medicament of the Sarmustine SarCNU of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin.
Sustained-release micro-spheres also can be used for preparing sustained-release implant, and used slow-release auxiliary material can be any or multiple material in the above-mentioned pharmaceutic adjuvant, is main separation with the high molecular weight water soluble polymer in various high molecular polymers.
Slow-release auxiliary material and percentage by weight thereof are most preferably as follows in the sustained-release implant of the present invention:
(1) PLA of 55-90%;
(2) PLGA of 50-90%;
(3) polifeprosan of 50-85%;
(4) bis-fatty acid of 55-90% and decanedioic acid copolymer;
(5) EVAc of 55-90%;
(6) xylitol of 40-95%, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or albumin glue; Or
(7) poly-dl-lactide of 40-95%, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Route of administration depends on multiple factor, for obtain valid density in former or position, metastatic tumour place, medicine can give through number of ways, as in subcutaneous, intracavity (in abdominal cavity, thoracic cavity and canalis spinalis), the tumor, in all injections of tumor or placement, selective arterial injection, the lymph node and injection in the bone marrow.With in selective arterial injection, intracavity, the tumor, tumor week injection or be placed as preferred.
The present invention can be used to prepare the pharmaceutical preparation of the various tumors for the treatment of people and animal, be mainly slow releasing injection or sustained-release implant, the indication tumor comprises former or cancer or sarcoma or the carcinosarcoma that shifts that originates from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Also can add other medicinal ingredient in slow releasing injection that the present invention is made or the sustained-release implant, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.
By following test and embodiment technology of the present invention is further described:
The local drug concentration that test 1, different modes are used behind the fotemustine compares
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 1 cm diameter its grouping.Every group of dosage is the 5mg/kg fotemustine.Measure medicament contg (%) in the different time tumor, the result shows, the local drug concentration significant difference of fotemustine after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.This discovery constitutes key character of the present invention.Following relevant inhibition test has further confirmed this point.
The interior tumor-inhibiting action of body that test 2, different modes are used behind the fotemustine compares
With the rat is subjects, with 2 * 10
5Individual prostate tumor cells subcutaneous injection is in its hypochondrium, treats behind tumor growth to 0.5 cm diameter its grouping.Every group of dosage is the 5mg/kg fotemustine.The treatment back was measured gross tumor volume size, relatively therapeutic effect on the 10th day.The result shows, the tumor-inhibiting action significant difference of fotemustine after different modes is used, topical can obviously improve and effectively keep the active drug concentration at position, tumor place, and is wherein best with the effect of placing sustained-release implant and intratumor injection slow releasing injection in the tumor.Yet, intratumor injection slow releasing injection operation most convenient, easy.Good effect not only, toxic and side effects is also little.
Tumor-inhibiting action in the body of test 3, nimustine and cell toxicity medicament (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual pancreatic tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 1).First group is contrast, and the 2nd to 10 group is the treatment group, and medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 1) on the 10th day.
Table 1
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 64±10 | |
| 2(6) | Nimustine | 42±5.2 | ＜0.05 |
| 3(6) | Hydroxy-camptothecin alkali | 40±2.2 | ＜0.01 |
| 4(6) | Mitozolomide | 44±2.6 | ＜0.01 |
| 5(6) | Docetaxel | 42±3.4 | ＜0.01 |
| 6(6) | Ifosfamide | 42±3.6 | ＜0.01 |
| 7(6) | Hydroxy-camptothecin alkali+nimustine | 18±2.0 | ＜0.001 |
| 8(6) | Mitozolomide+nimustine | 16±2.2 | ＜0.001 |
| 9(6) | Docetaxel+nimustine | 20±2.0 | ＜0.001 |
| 10(6) | Ifosfamide+nimustine | 18±2.0 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for nimustine and its synergist (hydroxy-camptothecin alkali, mitozolomide, docetaxel, ifosfamide), can show significant potentiation when use in conjunction.This discovery constitutes the another key character of the present invention.
The tumor-inhibiting action of test 4, estramustine and cell toxicity medicament (slow releasing injection)
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Estramustine and cell toxicity medicament are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.The result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used cell toxicity medicament (hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil, ametycin) and estramustine, can show significant potentiation when use in conjunction.
Same potentiation also sees the combination of hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin and fotemustine, bendamustine, nimustine, carmustine, lomustine, estramustine or Sarmustine SarCNU.
The tumor-inhibiting action of test 5, bendamustine and cell toxicity medicament (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual tumor cell of liver subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it following 10 groups (seeing Table 5).First group is contrast, and the 2nd to 10 group is the treatment group, and sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 3) on the 10th day.
Table 3
| Test group (n) | Suffered treatment | Gross tumor volume (cm 3) | The P value |
| 1(6) | Contrast | 66±12 | |
| 2(6) | Bendamustine | 44±4.2 | ＜0.05 |
| 3(6) | Docetaxel | 42±2.0 | ＜0.01 |
| 4(6) | Bendamustine+docetaxel | 16±2.2 | ＜0.001 |
| 5(6) | Etoposide | 38±3.2 | ＜0.01 |
| 6(6) | Bendamustine+etoposide | 20±1.6 | ＜0.001 |
| 7(6) | Teniposide | 32±2.6 | ＜0.01 |
| 8(6) | Bendamustine+teniposide | 18±2.0 | ＜0.001 |
| 9(6) | Vincaleucoblastine | 38±4.0 | ＜0.01 |
| 10(6) | Bendamustine+vincaleucoblastine | 20±2.0 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used fotemustine and cell toxicity medicament (docetaxel, etoposide, teniposide, vincaleucoblastine), can show significant potentiation when use in conjunction.This discovery constitutes the another key character of the present invention.
The tumor-inhibiting action of test 6, bendamustine and cell toxicity medicament (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual colon cancer tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group (bendamustine or cell toxicity medicament) and therapeutic alliance group (bendamustine and cell toxicity medicament).Medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, made relatively therapeutic effect (seeing Table 4) of index with inhibition rate of tumor growth.
Table 4
| Test group (n) | Suffered treatment | Tumor control rate (%) | The P value |
| 1(6) | Contrast | ||
| 2(6) | Bendamustine | 46 | ＜0.05 |
| 3(6) | Anastrozole | 36 | ＜0.01 |
| 4(6) | Tamoxifen | 44 | ＜0.01 |
| 5(6) | Fluorouracil | 52 | ＜0.01 |
| 6(6) | Ametycin | 42 | ＜0.01 |
| 7(6) | Bendamustine+Anastrozole | 72 | ＜0.001 |
| 8(6) | Bendamustine+tamoxifen | 80 | ＜0.001 |
| 9(6) | Bendamustine+fluorouracil | 82 | ＜0.001 |
| 10(6) | Bendamustine+ametycin | 82 | ＜0.001 |
Above result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used bendamustine and cell toxicity medicament (Anastrozole, tamoxifen, fluorouracil and ametycin), can show significant potentiation when use in conjunction.
The tumor-inhibiting action of test 7, fotemustine and cell toxicity medicament (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual lymphoma cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Medicine is through intratumor injection.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, make relatively therapeutic effect of index with inhibition rate of tumor growth, the result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used fotemustine and cell toxicity medicament (hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, 5-FU and ametycin), can show significant potentiation when use in conjunction.This discovery constitutes the another key character of the present invention.Same potentiation also sees the associating of nimustine or carmustine hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, 5-FU or ametycin.
The tumor-inhibiting action of test 8, lomustine and cell toxicity medicament (slow releasing injection)
With the rat is subjects, with 2 * 10
5Individual breast tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it negative control (blank), single therapy group, therapeutic alliance group.Sustained-release implant is placed in tumor.Dosage is 5mg/kg.The treatment back was measured the gross tumor volume size on the 10th day, make relatively therapeutic effect of index with inhibition rate of tumor growth, last result shows, growth all has the obvious suppression effect to kinds of tumor cells when this concentration is used separately for used lomustine and cell toxicity medicament (hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, 5-FU and ametycin), can show significant potentiation when use in conjunction.This discovery constitutes the another key character of the present invention.
Release ratio in the body of the Sarmustine SarCNU sustained-release implant that test 9, different molecular weight polylactic acid are made
With the rat is subjects, grouping (3/group) and the equivalent Sarmustine SarCNU sustained-release implant that carries in the subcutaneous polylactic acid (PLA) that contains different molecular weight (MW).Survey the surplus of medicine in implant respectively at 1,3,7,14,21,28 and 35 day then, and then draw rate of release (%) in its body.The result shows, molecular weight is 20000 is released to: 1 day (8%), 3 (28%), 7 (56%), 14 (82%), 21 (90), 28 (94) and 35 (98%).Discharge in the body of the Sarmustine SarCNU sustained-release implant that comparison different molecular weight polylactic acid is made and find, slack-off with the molecular weight increase, with the 7th day was example, compare with whole body administration group, the bacteriostatic rate increases with the polylactic acid molecule amount and improves, and is followed successively by 68% (MW:5000), 66% (MW:15000), 54% (MW:25000), 50% (MW:40000) and 48 (MW:60000).
That pays special attention to is simple to operation, the good reproducibility of slow releasing agent of the present invention, particularly slow releasing injection.Good effect not only, toxic and side effects is little.
Different drug packages is to want characteristic different with different Biodegradable high moleculars.Discover that further the slow-release auxiliary material that is most appropriate to medicament slow release of the present invention is a poly-dl-lactide, poly-dl-lactide/ethanol copolymer, the monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, the polyethylene glycol copolymer, end carboxyl polylactic acid, end carboxyl polylactic acid/ethanol copolymer, polifeprosan, bis-fatty acid and decanedioic acid copolymer, poly-(erucic acid dimer-decanedioic acid), poly-(fumaric acid-decanedioic acid), ethylene vinyl acetate copolymer, polylactic acid, the copolymer of polyglycolic acid and hydroxyacetic acid, xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin, one of albumin glue or its combination; Optimum suspending agent is one of methylcellulose, hydroxy methocel, sodium carboxymethyl cellulose, (iodine) glycerol, simethicone, propylene glycol, carbomer, mannitol, sorbitol, surfactant, soil temperature 20, soil temperature 40, soil temperature 80 or its combination.
In a word, growth all had the obvious suppression effect to kinds of tumor cells when used fotemustine and various cell toxicity medicament were used separately, can show significant potentiation when use in conjunction.Therefore, effective ingredient of the present invention is fotemustine and any one cell toxicity medicament.The medicine that contains above effective ingredient can be made into sustained-release micro-spheres, and then makes slow releasing injection and implant, serves as preferred with the suspensoid injectio that is combined to form with the special solvent that contains suspending agent wherein.
Slow releasing injection or sustained-release implant also can be further specified by following embodiment.Just the invention will be further described for the foregoing description and following examples, is not its content and use are imposed any restrictions.
(4) specific embodiment
Embodiment 1.
80mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg hydroxy-camptothecin alkali and 10mg fotemustine, shake up the back contains 10% hydroxy-camptothecin alkali and 10% fotemustine with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the normal saline that contains 15% mannitol, makes corresponding suspension type slow releasing injection, viscosity is 220cp-460cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method step that is processed into slow releasing injection is identical with embodiment 1, but different is that contained anticancer effective component and percentage by weight thereof are:
(1) cell toxicity medicament of the fotemustine of 2-40%, nimustine or carmustine and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(2) cell toxicity medicament of the bendamustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(3) cell toxicity medicament of the lomustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(4) cell toxicity medicament of the estramustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin; Or
(5) cell toxicity medicament of the Sarmustine SarCNU of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin.
Used adjuvant is: poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer; The viscosity of slow releasing injection is 10cp-650cp (20 ℃-30 ℃ time).
Embodiment 3.
With 70mg molecular weight peak value is that 65000 polylactic acid (PLGA, 75: 25) is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 15mg nimustine and 15mg mitozolomide, shakes up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 15% nimustine and 15% mitozolomide, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection, viscosity is 300cp-400cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 4
The method step that is processed into slow releasing injection is identical with embodiment 3, but different is that contained anticancer effective component and percentage by weight thereof are: the combination of the nimustine of the hydroxy-camptothecin alkali of 5-30%, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 2-40%.
Embodiment 5.
(EVAc) puts into container with the 70mg ethylene vinyl acetate copolymer, after adding 100 milliliters of dichloromethane dissolving mixings, add 20mg docetaxel and 10mg carmustine, shake up the back contains 20% docetaxel and 10% carmustine with spray drying method for preparation injectable microsphere again.Then microsphere is suspended in the injection that contains the 5-15% sorbitol, makes corresponding suspension type slow releasing injection, viscosity is 100cp-200cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 6.
The method step that is processed into slow releasing injection is identical with embodiment 5, but different is that contained anticancer effective component is: the combination of the carmustine of the hydroxy-camptothecin alkali of 10-20%, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 10-20%.
Embodiment 7.
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg Sarmustine SarCNU and 10mg ifosfamide, shake up the back contains 20% Sarmustine SarCNU and 10% ifosfamide with spray drying method for preparation injectable microsphere again.Microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 0.5% Tween 80 then, makes corresponding suspension type slow releasing injection, viscosity is 80cp-150cp (20 ℃-25 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 8.
The method step that is processed into slow releasing injection is identical with embodiment 7, but different is that contained anticancer effective component is: the combination of the Sarmustine SarCNU of the hydroxy-camptothecin alkali of 15-25%, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 15-25%.
Embodiment 9
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 20mg lomustine and 10mg vincaleucoblastine, shake up the back contains 20% lomustine and 10% with spray drying method for preparation vincaleucoblastine injectable microsphere again.Then microsphere is suspended in the normal saline that contains 1.5% sodium carboxymethyl cellulose and 15% sorbitol and 0.2% Tween 80, makes corresponding suspension type slow releasing injection, viscosity is 560cp-640cp (20 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 10
The method step that is processed into slow releasing injection is identical with embodiment 9, but different is that contained anticancer effective component is: the combination of the lomustine of 20% hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 20%.
Embodiment 11
70mg polifeprosan (to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 20: 80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg estramustine and 20mg fluorouracil, shake up the back contains 10% estramustine and 20% fluorouracil with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 30-40 days at the subcutaneous drug release time of mice.
Embodiment 12
The method step that is processed into sustained-release implant is identical with embodiment 11, but different is that contained anticancer effective component is: the combination of the estramustine of 10% hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 10%.
Embodiment 13
With 70mg molecular weight peak value 35000 polylactic acid (PLGA, 50: 50) put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg Sarmustine SarCNU and 20mg vincaleucoblastine, shake up the back contains 10% Sarmustine SarCNU and 20% vincaleucoblastine with spray drying method for preparation injectable microsphere again.Then microsphere is made corresponding sustained-release implant through pressed disc method.The drug release time of this sustained-release implant in external normal saline is 10-15 days, is about 35-50 days at the subcutaneous drug release time of mice.
Embodiment 14
The method step that is processed into sustained-release implant is identical with embodiment 11,13, but different is that contained anticancer effective component is: the combination of the Sarmustine SarCNU of the hydroxy-camptothecin alkali of 5-25%, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 5-25%.
Embodiment 15.
With 70mg molecular weight peak value is that 35000 polylactic acid (PLA) is put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 15mg fluorouracil and 15mg fotemustine, shakes up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 15% fluorouracil and 15% fotemustine, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection, viscosity is 220cp-260cp (25 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 16
The method step that is processed into slow releasing injection is identical with embodiment 15, but different is that contained anticancer effective component and percentage by weight thereof are: the combination of the fotemustine of 15% hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin and 15%.
Embodiment 17.
With 70mg molecular weight peak value is that 30000 bis-fatty acid and certain herbaceous plants with big flowers diacid (SA) copolymer (bis-fatty acid: the certain herbaceous plants with big flowers diacid is 20: 80) are put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 15mg carmustine and 15mg vincaleucoblastine, shake up the dry organic solvent of removing of final vacuum again.Dried pastille solid composite freezing and pulverizing is made the micropowder that contains 15% carmustine and 15% vincaleucoblastine, be suspended in then in the normal saline that contains 1.5% sodium carboxymethyl cellulose, make corresponding suspension type slow releasing injection, viscosity is 380cp-460cp (25 ℃-30 ℃ time).The drug release time of this slow releasing injection in external normal saline is 10-15 days, is about 20-30 days at the subcutaneous drug release time of mice.
Embodiment 18.
The method step that is processed into slow releasing injection is identical with embodiment 17, but different is that contained anticancer effective component and percentage by weight thereof are:
The combination of 15% lomustine, estramustine, carmustine, nimustine, fotemustine, Sarmustine SarCNU or bendamustine and 15% etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or ametycin.
Embodiment 19
The method step that is processed into slow releasing agent is identical with embodiment 1-18, but different is used slow-release auxiliary material is one of following or its combination:
A) polylactic acid (PLA), the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
B) copolymer of polyglycolic acid and hydroxyacetic acid (PLGA), wherein, the ratio of polyglycolic acid and hydroxyacetic acid is 50-95: 50-50, the molecular weight peak value is 10000-30000,300000-60000,60000-100000 or 100000-150000;
C) ethylene vinyl acetate copolymer (EVAc);
D) polifeprosan, to carboxy phenyl propane (p-CPP): certain herbaceous plants with big flowers diacid (SA) is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
E) bis-fatty acid and decanedioic acid copolymer (PFAD-SA);
F) poly-(erucic acid dimer-decanedioic acid) [P (EAD-SA)];
G) poly-(fumaric acid-decanedioic acid) [P (FA-SA)];
H) xylitol, oligosaccharide, chrondroitin, chitin, hyaluronic acid, collagen protein, gelatin or white tempera;
I) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer.
Embodiment 20
The method step that is processed into slow releasing injection is identical with embodiment 1-19, but different is used suspending agent is respectively one of following or its combination:
A) 0.5-3.0% carboxymethyl cellulose (sodium);
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20.
Embodiment 21
The method step that is processed into slow releasing injection is identical with embodiment 1-20, but different is that contained anticancer effective component is: the combination of hydroxy-camptothecin alkali, mitozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil or the ametycin of 2-20% and fotemustine, lomustine, estramustine, nimustine, carmustine, bendamustine or the Sarmustine SarCNU of 2-20%.
Embodiment 22
The method step that is processed into slow releasing injection is identical with embodiment 1-20, but different is that contained anticancer effective component is:
(1) cell toxicity medicament of the fotemustine of 2-40%, carmustine or nimustine and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(2) cell toxicity medicament of the bendamustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(3) cell toxicity medicament of the lomustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin;
(4) cell toxicity medicament of the estramustine of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin; Or
(5) cell toxicity medicament of the Sarmustine SarCNU of 2-40% and 2-40% comprises the combination that is selected from hydroxy-camptothecin alkali, mitozolomide, 4-carboxyl temozolomide, docetaxel, ifosfamide, etoposide, teniposide, vincaleucoblastine, Anastrozole, tamoxifen, fluorouracil (5-FU) or ametycin.
Above embodiment only is used for explanation, and is not limitation application of the present invention.
The present invention disclosed and the protection the content see claim.
Claims (6)
1. slow-releasing anticarcinogen injection is grouped into by following one-tenth:
(A) sustained-release micro-spheres comprises:
Anticancer effective component 0.5-60%
Slow-release auxiliary material 40-99%
Suspending agent 0.0-30%
More than be weight percentage
With
(B) solvent is for common solvent or contain the special solvent of suspending agent;
Wherein,
Anticancer effective component is the combination of this class medicine of fotemustine, lomustine, estramustine, nimustine, carmustine, bendamustine or Sarmustine SarCNU and cell toxicity medicament;
Described cell toxicity medicament is a docetaxel;
Slow-release auxiliary material is selected from one of following or its combination:
A) polylactic acid, its molecular weight peak value is 10000-30000,30000-60000,60000-100000 or 100000-150000;
B) copolymer of polylactic acid and hydroxyacetic acid, wherein, the ratio of polylactic acid and hydroxyacetic acid is 10/90-90/10, the molecular weight peak value is 10000-30000,30000-60000,60000-100000 or 100000-150000;
C) polifeprosan, wherein, to carboxy phenyl propane: decanedioic acid is 10: 90,20: 80,30: 70,40: 60,50: 50 or 60: 40;
D) ethylene vinyl acetate copolymer;
E) bis-fatty acid and decanedioic acid copolymer;
F) poly-(erucic acid dimer-decanedioic acid) copolymer;
G) poly-(fumaric acid-decanedioic acid) copolymer;
H) poly-dl-lactide, poly-dl-lactide/ethanol copolymer, monomethyl polyethylene glycol, monomethyl polyethylene glycol copolymer, polyethylene glycol, polyethylene glycol copolymer, end carboxyl polylactic acid or end carboxyl polylactic acid/ethanol copolymer;
The viscosity of suspending agent is 100cp-3000cp (20 ℃-30 ℃ time), is selected from one of following or its combination:
A) 0.5-3.0% sodium carboxymethyl cellulose;
B) 5-15% mannitol;
C) 5-15% sorbitol;
D) 0.1-1.5% surfactant;
E) 0.1-0.5% polysorbas20;
F) iodine glycerol, simethicone, propylene glycol or carbomer;
G) 0.55% sodium carboxymethyl cellulose+0.1-0.5% Tween 80;
H) 520% mannitol+0.1-0.5% Tween 80; Or
I) 0.5-5% sodium carboxymethyl cellulose+5-20% sorbitol+0.1-0.5% Tween 80.
2. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that the weight ratio of this class medicine of fotemustine, lomustine, estramustine, nimustine, carmustine, bendamustine or Sarmustine SarCNU and cell toxicity medicament is 1-9: 1 to 1: 1-9.
3. the slow-releasing anticarcinogen injection according to claim 1 is characterized in that the anticancer effective component of slow-releasing anticarcinogen injection and percentage by weight are:
(1) combination of the cell toxicity medicament docetaxel of the fotemustine of 2-40%, nimustine or carmustine and 2-40%;
(2) combination of the cell toxicity medicament docetaxel of the bendamustine of 2-40% and 2-40%;
(3) combination of the cell toxicity medicament docetaxel of the lomustine of 2-40% and 2-40%;
(4) combination of the cell toxicity medicament docetaxel of the estramustine of 2-40% and 2-40%; Or
(5) combination of the cell toxicity medicament docetaxel of the Sarmustine SarCNU of 2-40% and 2-40%.
4. the slow-releasing anticarcinogen injection according to claim 1, the component that it is characterized in that slow-releasing anticarcinogen injection is one of following combination:
Anticancer effective component is 20% docetaxel and 10% carmustine, and slow-release auxiliary material is an ethylene vinyl acetate copolymer, and solvent is the injection that contains the 5-15% sorbitol.
5. the slow-releasing anticarcinogen injection according to claim 1, it is characterized in that sustained-release micro-spheres in the slow-releasing anticarcinogen injection also is used for the preparation treatment and originates from people and animal brain, the central nervous system, kidney, liver, gallbladder, incidence, the oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, the uterus, ovary, endometrium, cervix uteri, prostate, bladder, former or the cancer of secondary of colon or rectum, the sustained-release implant of sarcoma or carcinosarcoma is in tumor or tumor week injection or place administration.
6. the anti-cancer sustained-released implantation agent according to claim 5 is characterized in that the sustained-release implant anticancer effective component is:
(1) combination of the cell toxicity medicament docetaxel of the fotemustine of 2-40%, nimustine or carmustine and 2-40%;
(2) combination of the cell toxicity medicament docetaxel of the bendamustine of 2-40% and 2-40%;
(3) combination of the cell toxicity medicament docetaxel of the lomustine of 2-40% and 2-40%;
(4) the cell toxicity medicament docetaxel of the estramustine of 2-40% and 2-40%; Or
(5) combination of the cell toxicity medicament docetaxel of the Sarmustine SarCNU of 2-40% and 2-40%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103002342A CN101234085A (en) | 2006-07-25 | 2006-07-25 | Docetaxel-containing anti-cancer sustained-release injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008103002342A CN101234085A (en) | 2006-07-25 | 2006-07-25 | Docetaxel-containing anti-cancer sustained-release injection |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2006102007316A Division CN1887265A (en) | 2006-07-25 | 2006-07-25 | Slow released anticancer prepn |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101234085A true CN101234085A (en) | 2008-08-06 |
Family
ID=39918156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008103002342A Pending CN101234085A (en) | 2006-07-25 | 2006-07-25 | Docetaxel-containing anti-cancer sustained-release injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101234085A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920694A (en) * | 2012-10-31 | 2013-02-13 | 北京易明康元医药科技有限公司 | Pharmaceutical composition with anti-tumor effect and preparation thereof |
-
2006
- 2006-07-25 CN CNA2008103002342A patent/CN101234085A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102920694A (en) * | 2012-10-31 | 2013-02-13 | 北京易明康元医药科技有限公司 | Pharmaceutical composition with anti-tumor effect and preparation thereof |
| CN102920694B (en) * | 2012-10-31 | 2014-02-19 | 北京易明康元医药科技有限公司 | Pharmaceutical composition with anti-tumor effect and preparation thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1969818A (en) | Anticancer sustained release injection containing epothilone derivatives | |
| CN101396342A (en) | Anti-cancer sustained-released injection containing epothilone derivate | |
| CN101396340A (en) | Anti-cancer sustained-released injection containing epothilone derivate | |
| CN101336899A (en) | Anticancer sustained-released injection containing taxane | |
| CN101380303A (en) | Anti-cancer medicine sustained-released injection loaded with platinum compound and synergist thereof | |
| CN1969825A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
| CN101234084A (en) | Fluorouracil containing anti-cancer sustained-release injection | |
| CN1875936B (en) | Anticancer sustained release agent containing clorfarabine and cytotoxic drug | |
| CN101234085A (en) | Docetaxel-containing anti-cancer sustained-release injection | |
| CN100569289C (en) | The anticancer pharmaceutical composition of loaded with platinum compound and clofarabine | |
| CN101234087A (en) | Poside containing anti-cancer sustained-release injection | |
| CN1969823A (en) | Sustained release agent containing fluorouracil and synergist thereof | |
| CN1969824A (en) | Anticancer sustained release agent containing fluorouracil and synergist thereof | |
| CN101269008A (en) | Novel anticancer sustained-release agent | |
| CN100998558A (en) | Slow-release anticarcinogen contg. carmustine and fluorouracil | |
| CN101011345A (en) | Slow release injection containing platinum compound and alkylating agent | |
| CN1957920B (en) | Anti cancer slow release agent carrying fluorouracil and synergist | |
| CN101234086A (en) | Hydroxycamptothecin containing anti-cancer sustained-release injection | |
| CN100594887C (en) | Anticancer slow release injection comprising tetrazole violet and potentiating agent thereof | |
| CN1919174B (en) | Anticancer slow release agent including nimustine and its synergist | |
| CN100464737C (en) | Medicinal composition of nimustine and its progression agent | |
| CN101427996A (en) | Novel anticancer sustained-release injection | |
| CN1969826A (en) | Fluorouracil and its synergist carried sustained release agent | |
| CN100531715C (en) | Slow-released methotrexate injection | |
| CN101269009A (en) | Novel anticancer injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080806 |